Скачать или смотреть Sean McAllister on FDA's Decision on MDMA, Colorado Psychedelic Rules, and Ketamine Therapy

Join Justin Botillier, CEO of Calyx CPA, in an enlightening interview with Sean McAllister, a prominent attorney specializing in psychedelics. In this video, Sean shares his expert insights on the recent FDA advisory panel's decision regarding MDMA approval, Colorado's progressive psychedelic regulations, and the legal complexities surrounding ketamine therapy. Discover the implications of these developments for the psychedelic therapy industry and gain valuable knowledge about navigating the legal landscape of psychedelic substances.

Sean McAllister, known for his pioneering work in cannabis and psychedelics, discusses:

The FDA advisory panel's recent recommendation on MDMA, potential delays in its approval, and the institutional resistance faced by psychedelic therapies.
Colorado's innovative approach to psychedelic regulation, including full decriminalization and the legal framework for sharing natural medicines.
The legal and practical aspects of ketamine therapy emphasize the importance of proper medical supervision and the potential pitfalls for practitioners.
Don't miss this in-depth conversation that covers:

The role of insurance companies and institutional biases in the FDA's decision on MDMA.
Legal strategies for doctors and therapists in the psychedelic industry.
The significance of harm reduction and patient safety in ketamine therapy.
Opportunities in Colorado's decriminalized environment for psychedelic services and the legal nuances involved.
For more information on Sean McAllister's work and expertise, visit McAllister Law Office.

#MDMA #FDA #PsychedelicTherapy #SeanMcAllister #PsychedelicLawyer #CalyxCPA #Psychedelics #MentalHealth #PsychedelicScience #CannabisLaw #HarmReduction #ColoradoPsychedelics #KetamineTherapy